

OIE Reference Laboratory Reports Activities

Activities in 2017

This report has been submitted : 2018-01-25 10:49:14

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	African horse sickness
Address of laboratory:	Ash Road, Pirbright Woking, Surrey, GU24 0NF UNITED KINGDOM
Tel.:	+44-1483 23 24 41
Fax:	+44-1483 23 24 48
E-mail address:	javier.castillo-olivares@pirbright.ac.uk
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Bryan Charlston
Name (including Title and Position) of OIE Reference Expert:	Dr Javier Castillo-Olivares
Which of the following defines your laboratory? Check all that apply:	Research

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests		Nationally	Internationally
Ab ELISA	Yes	335	233
Direct diagnostic tests		Nationally	Internationally
Real-time RT-PCR	Yes	0	0

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards. To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
AHSV-9 RNA	PCR	Provide	0	1ml	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
AHSV-4 serum	ELISA/NT	Provide	0	1ml	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
AHSV- 9 isolates	vector competence studies	Provide	0	5ml	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

No

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Evaluation of AHS ELISA for improved surveillance	1 year	Improved control of AHS	The Pirbright Institute, ANSES, LCV (Algete, Spain) Deltamune, OVI, IZS (Teramo) USDA (Iowa) UCM (Madrid)	FRANCE ITALY SOUTH AFRICA SPAIN UNITED STATES OF AMERICA
Economic assessment of AHSV vaccines impact	1.5 years	Improved control of AHS	The Pirbright Institute, RVC, (Univ Liverpool)	
Evaluation of AHSV vaccine candidates with DIVA capacity	1.5 years	Improved control of AHS	The Pirbright Institute, ANSES, LCV (Algete, Spain) Deltamune, OVI, IZS (Teramo) USDA (Iowa) UCM (Madrid) Univ of Wageningen	FRANCE ITALY SOUTH AFRICA SPAIN THE NETHERLANDS UNITED STATES OF AMERICA

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

**13. What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 1

Manning, Nicola & Bachanek-Bankowska, Katarzyna & Paul Clement Mertens, Peter & Castillo-Olivares, Javier. (2017). Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination. Vaccine. 35. . 10.1016/j.vaccine.2017.04.005.

b) International conferences: 0

c) National conferences: 0

d) Other:

(Provide website address or link to appropriate information) 0

**ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards**

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

a) Technical visits: 0

b) Seminars: 0

c) Hands-on training courses: 2

d) Internships (>1 month): 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
c	Finland	1
c	Japan	1

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity

relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System certified according to an International Standard?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO/IEC 17025	UKAS Scope.pdf

16. Is your laboratory accredited by an international accreditation body?

Yes

Test for which your laboratory is accredited	Accreditation body
Real-time RT-PCR	UKAS
Ab ELISA	UKAS
Virus isolation	UKAS

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

Purpose of the proficiency tests: ¹	Role of your Reference Laboratory (organiser/ participant)	No. participants	Participating OIE Ref. Labs/ organising OIE Ref. Lab.
Detection of genome and Ab to AHSV	Participant	41	Pirbright, UK and South Africa. Organiser Spain

¹ validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
Evaluation of AHS ELISA for improved surveillance	Improved control of AHS	TPI, ANSES, LCV(Algete), Deltamune, OVI, IZS (Teramo), USDA (Iowa), UCM (Madrid)
Economic assessment of AHSV vaccines impact	Improved control of AHS	TPI, RVC, (Univ. Liverpool)
Evaluation of AHSV vaccine candidates with DIVA capability	Improved control of AHS	TPI, ANSES, LCV(Algete), Deltamune, OVI, IZS (Teramo), USDA (Iowa), UCM (Madrid) Univ. of Wageningen

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons ¹	No. participating laboratories	Region(s) of participating OIE Member Countries
Detection of genome and Abs to AHSV	41	<input checked="" type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
Review the outputs of the three OIE funded AHSV projects	Paris 13th September	Control of AHSV

25. Additional comments regarding your report: